Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases

J Clin Endocrinol Metab. 2014 Mar;99(3):699-700. doi: 10.1210/jc.2013-3563. Epub 2014 Jan 1.

Authors

Marcela Paula Ferraz¹, Tomoco Watanabe, Heitor Naoki Sado, Carla Rachel Ono, Carlos Alberto Buchpiguel, Pedro Henrique Silveira Correa, Regina Matsunaga Martin

Affiliation

¹ Osteometabolic Disorders Unit, Division of Endocrinology and Center of Nuclear Medicine, Division of Radiology, Hospital das Clínicas, University of São Paulo, São Paulo 05403-900, Brazil.

PMID: 24423352
DOI: 10.1210/jc.2013-3563

No abstract available

Publication types

Case Reports
Research Support, Non-U.S. Gov't

MeSH terms

Adolescent
Adult
Aged
Female
Humans
Male
Middle Aged
Monitoring, Physiologic / standards
Neoplasms / complications
Neoplasms / diagnostic imaging*
Octreotide / analogs & derivatives*
Osteomalacia / diagnostic imaging*
Osteomalacia / etiology
Paraneoplastic Syndromes / diagnostic imaging
Radionuclide Imaging
Reproducibility of Results
Technetium Tc 99m Sestamibi*
Whole Body Imaging / methods*
Young Adult

Substances

indium-111-octreotide
Technetium Tc 99m Sestamibi
Octreotide